<DOC>
	<DOCNO>NCT02160626</DOCNO>
	<brief_summary>The main objective study evaluate dose-response relationship two concentration A-101 solution apply individual seborrheic keratosis ( SK ) lesion ( target lesion ) compare match A-101 Solution Vehicle .</brief_summary>
	<brief_title>Dose-Response Profile A-101 Subjects With Seborrheic Keratosis</brief_title>
	<detailed_description>The main objective study evaluate dose-response relationship two concentration A-101solution apply individual seborrheic keratosis ( SK ) lesion ( target lesion ) compare match A-101 Solution Vehicle . Each subject 4 target lesion trunk/extremities . A objective evaluate safety efficacy two concentration A-101 solution match vehicle apply SK target lesion trunk/extremities .</detailed_description>
	<mesh_term>Keratosis</mesh_term>
	<mesh_term>Keratosis , Actinic</mesh_term>
	<mesh_term>Keratosis , Seborrheic</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>1 . Subject least 18 year age 2 . Subject clinical diagnosis stable clinically typical seborrheic keratosis 3 . Subject 4 appropriate seborrheic keratosis target lesion , define ( Section 5.4 ) , trunk/extremities : Have clinically typical appearance Be treatment naïve Have PLA ≥2 ( Section 6.1.2 ) Have long axis ≥7mm ≤15mm ( Section 6.1.3 ) Have long dimension perpendicular long axis ≥7mm ≤15mm ( Section 6.1.3 ) Have thickness ≤3mm Be discrete lesion Be , center area outline provide 3cm diameter circular template , seborrheic keratosis lesion present Not intertriginous fold Not area clothing , bra , might cause physical irritation Not pedunculated . 4 . If subject woman childbearing potential , negative urine pregnancy test agree use active form birth control duration study 5 . Subject nonpregnant nonlactating 6 . Subject good general health free know disease state physical condition , investigator 's opinion , might impair evaluation target lesion expose subject unacceptable risk study participation 7 . Subject willing able follow study instruction attend study visit 8 . Subject able comprehend willing sign Informed Consent Form ( ICF ) . 1 . Subject clinically atypical and/or rapidly grow seborrheic keratosis lesion 2 . Subject presence multiple eruptive seborrheic keratosis lesion ( Sign LesserTrelat ) 3 . Subject current systemic malignancy 4 . Subject history keloid formation hypertrophic scar 5 . Subject use follow systemic therapy within specified period prior Visit 1 : Retinoids ; 180 day Glucocorticosteroids ; 28 day Antimetabolites ( e.g. , methotrexate ) ; 28 day 6 . Subject use follow topical therapy within specified period prior Visit 1 , proximity target lesion , investigator 's opinion , interfere application study medication study assessment : LASER , light ( e.g. , intense pulse light [ IPL ] , photodynamic therapy [ PDT ] ) energy base therapy ; 180 day Retinoids ; 90 day Liquid nitrogen , electrodesiccation , curettage , imiquimod , 5fluorouracil , ingenol mebutate ; 60 day Glucocorticosteroids antibiotic ; 14 day Moisturizers/emollients , sunscreens ; 12 hour 7 . Subject currently follow within specified period prior Visit 1 proximity target lesion , investigator 's opinion , interfere application study medication study assessment : A cutaneous malignancy ; 180 day Experienced sunburn ; 28 day A premalignancy ( e.g. , actinic keratosis ) ; currently Body art ( e.g. , tattoo , piercing , etc . ) ; currently Excessive tan ; currently 8 . Subject history sensitivity ingredient study medication 9 . Subject current skin disease ( e.g. , psoriasis , atopic dermatitis , eczema , sun damage , etc . ) , condition ( e.g. , sunburn , excessive hair , open wound ) , opinion investigator , might put subject undue risk study participation interfere study conduct evaluation 10 . Subject participate investigational drug trial administration investigational study medication occur within 30 day prior Visit 1 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Seborrheic keratosis</keyword>
	<keyword>A101</keyword>
</DOC>